An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

by | Jul 3, 2024 | Clinical Trials, Ensayos Clínicos - CIMO-01 | 0 comments

ANA GODOY ORTIZ – ENSAYO CLÍNICO CON MEDICAMENTOS – SERMONIX PHARMACEUTICALS, INC